FDX2

Across TCGA pan-cancer cohorts, FDX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FDX2 data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FDX2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FDX2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where FDX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.240	0.761	.001	27	view →
LSCC	OS	Median	II,III,IV	1.000	0.879	.015	15	view →
PDAC	OS	Median	III,IV	1.000	0.537	.013	6	view →
LUAD	DFS	Tertile	All	0.866	0.680	.017	2	view →
HNSC	OS	Quartile	All	0.744	0.921	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FDX2–CCRCC (DFS)

Open the CCRCC breakdown →